A message from 340B Report Publisher and CEO Ted Slafsky: We are pleased to have a sponsored content article today from Michael Gonzalez, President and Lead Consultant, FQHC340B, a valued 340B Report sponsor. I encourage you to read it. We will
…Category: Pharma Industry
A message from 340B Report Publisher and CEO Ted Slafsky: We are pleased to have a sponsored content piece today from Powers Law, based in Washington, D.C. We will have more information about 340B Report sponsorship packages for 2021 in
…AstraZeneca and Sanofi Block Access to 340B Contract Pharmacy Pricing, Novartis Does Not (UPDATED)
(UPDATED Friday Oct. 2, 2020, 4:30 p.m. EDT)
Congressman Grills Novartis Executive About Steps to Limit 340B Discounts
A Republican U.S. congressman from rural central Pennsylvania
…A message from 340B Report Publisher and CEO Ted Slafsky: We are pleased to have a sponsored content piece today by Equiscript CEO Michael Burkhold. I encourage you to read it. We will have more information about 340B Report
…Only 30 Providers Are Supplying Merck with Requested 340B Claims Data
Only 30—less than 1 percent—of the 340B covered entities that drug manufacturer Merck wrote to this summer seeking their contract pharmacy claims data are sharing their data with Merck
…Novartis Says It’s Weighing Whether to Start Cutting Off 340B Contract Pharmacy Discounts on Oct. 1. Sanofi Says it Will.
(Update 1, Friday Sept. 25, 1:00 p.m. EDT—Merck is “considering any next steps in our effort to ensure compliance with
…Note from 340B Report Publisher and CEO Ted Slafsky: I look forward to moderating a panel on the latest 340B developments, President Trump’s drug pricing executive orders, as well as the upcoming elections this Tuesday, Sept. 29 at 12:00
…HHS Top Lawyer Tells Lilly, Don’t Assume We Endorse Your 340B Policy
The top lawyer at the U.S. Health and Human Services (HHS) department told drug manufacturer Eli Lilly and Co. in a letter dated Sept. 21 and made
…Breaking News
BREAKING: 22 U.S. Senate Democrats Want Answers from PhRMA About its Members’ 340B Actions
22 U.S. Senate Democrats Want Answers from PhRMA About its Members’ 340B Actions
Twenty-two Democratic U.S. senators asked Pharmaceutical Research and Manufacturers of America (PhRMA) today to inform them by no later than Sept. 29 “regarding steps being taken by
…